Post by
cancerman24 on Jan 24, 2024 2:30pm
CG Oncology phase 3 results impossible for TLT to beat?
75.7% complete response rate at any time in phase 3. Announced Nov 30 2023 so may all know about it already.
Not bashing, just asking.
Comment by
livermore2 on Jan 24, 2024 8:35pm
It's a combo treatment with Keytruda we are currently a standalone. This IPO may bring some eyes on us to show what kind of valuation a bladder treatment warrants.
Comment by
Eoganacht on Jan 25, 2024 12:14am
They have a phase 3 standalone trial and a phase 2 combo with Keytruda.
Comment by
livermore2 on Jan 25, 2024 8:23am
Thanks for clarifying that. Well looks like they have a hot IPO today which will be valued over 1B on the Nasdaq.https://www.morningstar.com/news/marketwatch/20240125223/cg-oncology-ipo-prices-above-range-and-boosts-share-count-in-bullish-move-ahead-of-trading
Comment by
Gman620 on Jan 25, 2024 10:12am
Why should TLT get BTD with this out there? Having lots of treatments and working with Keytruda is the exact sweet spot big pharma wants, hence their big money backers. Hard not to see this as a dagger to TLT. As I've said before, if it has a high success rate, no one, especially patients, cares about number of treatments. That's what pharma wants anyway.
Comment by
Longholder99 on Jan 25, 2024 10:52am
The 75% of all people who dont match the genrtic profile and therefore can't take Keytruda, or don't want the laundry list of side effects immuno modifying drugs bring....they probably care.
Comment by
Rumpl3StiltSkin on Jan 25, 2024 11:53am
Exactly! 75% of ˜25% plus it is a pain to be on this compared to what TLT offers. Ruvidar doesn't have these restrictions.
Comment by
Longholder99 on Jan 26, 2024 7:53am
Great post wildbird. Haven't seen this pp of which some speak either. I suppose if you keep saying it's going to rain until it eventually does you can claim you were right.